Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3- methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl] thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Espino says shes always experienced her weight as a difficult-to-manage chronic disease, and she sees GLP-1 as a pragmatic approach to a long-standing problem
Patients should be advised that "GLP-1 probiotic" marketing claims are not FDA-evaluated and may be misleading
Following the restructuring and exit of structured debt holders, interest costs are expected to decline by around Rs 300 crore year-on-year in FY27, while capex is also set to moderate as most major expansions have been completed, said Aman Goyal, Research Associate at Axis Securities
2004, 287 (6): E1209-E1215